Prot # 003-23: A Phase II Randomized, Partially Blinded, Pilot Study to Evaluate the Efficacy and Safety of MK-5172 in Combination with Ribavirin (RBV) in Treatment-Naive (TN) Patients with Chronic Genotype 1 (GT 1) Hepatitis C Virus Infection" MK-5172-03

Project: Research project

Project Details

Effective start/end date6/1/126/1/13


  • Merck Sharp & Dohme Corporation (Prot # 003-23)